Development and Evaluation of Lipidic Nanocarriers for the Treatment of Lung Carcinoma

Abstract

Lung cancer is the chief main cause of cancer-related deaths worldwide. Non small-cell lung cancer (NSCLC) is the most among them. Among all the agents Endothelial Growth Factor Receptor (EGFR inhibitors) are actively expressed in tumor cells by blocking EGFR signalling and thereby controlling the tumor cell growth. In the most prominent causes of death, these days like cancer, cytotoxic drugs hold the first place in treatment (Breast cancer is an exception newlinewere immunotherapy is used). Gefitinib (Gef) is the first-line drug for the treatment of non-small lung cancer (NSCLC) with activating endothelial growth factor receptor mutations (EGFR). Gefitinib belongs to the BCS Class II molecule. The objective of this research work was to increase the solubility of Gefitinib by encapsulating it into the lipidic matrix and thereby increasing its bioavailability at the target site. These nanocarriers are the small-sized particles that contain the scaffold (Lipids) which can entrap the lipophilic drug moiety in it, forming a lipid-drug matrix ensuring high solubility of the drug and enhanced permeability. These nanocarrier entrapped drugs attack the tumor proliferative cells and gets embedded in it newline(Passive targeting) also called permeation with retention effect. Response surface methodology is used with the purpose to create the best performance system by optimizing the levels of these variables collectively. The systematic formulation designs are involved in the optimization newlineprocedure to substantially reduce the number of trails and analyze the response surfaces so that the effects of casual factors can be realized and appropriate formulations with the target goals can be obtained.